In this issue:
Genomic analysis identifies a high-risk, double-hit, group of NDMM
TOURMALINE-MM3: Oral ixazomib maintenance following ASCT
Efficacy of first-line treatments for transplant-ineligible MM patients
Addition of cyclophosphamide to lenalidomide-dexamethasone in patients with RRMM
Carfilzomib vs bortezomib in patients with MM and renal failure
Immune signatures associated with clonal isotype switch after
ASCT for MM
Benefit of additional treatment to the standard MM treatment protocol
Primary thromboembolic prevention in MM patients
Carfilzomib-induced aHUS responds to early eculizumab
Selinexor for patients with RRMM
Please login below to download this issue (PDF)